Back to search
Publication

Clinical trial of fusidic acid for lepromatous leprosy.

Abstract

Fusidic acid was assessed for antileprosy activity in nine lepromatous leprosy patients. Patients received fusidic acid at either 500 mg/day for 12 weeks or 750 mg/day for 4 weeks followed by 500 mg/day for 8 weeks. All patients showed time-dependent clinical improvement and decreases in bacillary morphological index, radiorespirometric activity and PCR signal, and in serum phenolic glycolipid I. Fusidic acid appears to be a weakly bactericidal antileprosy agent which may have a role in the multidrug treatment of leprosy pending an evaluation of lepra-reaction-suppressive activity.

More information

Type
Journal Article
Author
Franzblau S G
Chan G P
Garcia-Ignacio B G
Chavez V E
Livelo J B
Jimenez C L
Parrilla M L
Calvo R F
Williams D L
Gillis T P
Year of Publication
1994
Journal
Antimicrobial agents and chemotherapy
Volume
38
Issue
7
Number of Pages
1651-4
Date Published
1994 Jul
Language
eng
ISSN Number
0066-4804
DOI
10.1128/aac.38.7.1651
Alternate Journal
Antimicrob. Agents Chemother.
Publication Language
eng

More publications on: